Sequencio Therapeutics Company Limited, a subsidiary of CK Life Sciences Int’l., (Holdings) Inc., announced that the Society for Immunotherapy of Cancer (SITC) has selected two abstracts from the company for poster presentation at its 41st Annual Meeting, taking place 4-8 November 2026 in Phoenix, Arizona. The studies evaluated key elements of Sequencio’s Prime–Infiltrate–Ignite–Translate (PINT) translational research framework, according to a company announcement carried by Media OutReach Newswire.
The two vaccine programmes address central challenges in cancer immunotherapy: helping the immune system recognize and attack cancer cells, and overcoming mechanisms that tumors use to evade immune responses. Both vaccines generated targeted immune responses against their intended cancer-related targets, supporting the “Prime” element of the PINT framework. The TROP2 vaccine combination increased activated T cells within tumors, while the PD-L1/PRAME vaccine increased tumor-infiltrating immune cells and other indicators of local immune activity, supporting “Infiltrate.” The use of checkpoint targeting and evidence of a more immune-active tumor environment support “Ignite,” and the use of humanized preclinical models contributes to “Translate” by helping researchers assess how the findings may be relevant to humans.
In the first study, Sequencio’s hTROP2-targeted circRNA-LNP therapeutic cancer vaccine, CKLS118, was evaluated in combination with anti-PD-1 therapy in two TROP2-positive tumor models. The vaccine enhanced the anti-tumor activity of lower-dose anti-PD-1 treatment compared with the corresponding monotherapies and significantly increased activated IFN-γ-positive CD4+ and CD8α+ T-cell subsets within tumors. In the 4T1-hTROP2 model, tumor growth inhibition reached 74.7% and 88.9% when the vaccine was combined with 0.3 and 1.0 mg/kg anti-PD-1, respectively, compared with 28.9% and 68.6% with anti-PD-1 alone. The findings support further development of CKLS118 in combination with checkpoint inhibition and evaluation of a potential dose-sparing strategy.
The second study evaluated Sequencio’s human PD-L1/PRAME dual-antigen vaccine, CKLS202, designed to combine tumor-antigen targeting with PD-L1-directed immune modulation. In humanized models, vaccination induced robust PRAME-specific T-cell responses, anti-human PD-L1 antibody titres above 1:16,000 and functional hPD-1/hPD-L1 blockade. In the efficacy model, vaccination achieved 65% tumor growth inhibition and was associated with increased tumor-infiltrating CD4+ cells (from 0.94% to 2.97%), more than twofold increases in interferon-γ and granzyme B, and a more than fivefold reduction in the M2 macrophage marker CD163, consistent with a shift toward a more immune-active tumor environment. Vaccinated tumor-free mice were also protected against tumor rechallenge, supporting durable antigen-specific immunity.
Dr Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences, said the two posters provide an important opportunity to share new data with the international immuno-oncology community and provide preclinical evidence supporting the intended mechanisms of action of the cancer vaccines. He added that while the two programmes take distinct approaches, both are designed to engage multiple elements of the PINT framework, and the findings may help inform future clinical development in peri-operative settings, where lower tumor burden may give vaccine-induced immunity a greater opportunity to control residual disease.
The presentations matter because they offer the first public look at two complementary vaccine strategies from Sequencio and suggest both candidates are moving toward human testing. The data remain preclinical, but the combination of meaningful tumor growth inhibition and durable immune responses provides a rationale for continued advancement of both vaccine candidates toward clinical trials.
